share_log

Additional Considerations Required While Assessing Suzhou Highfine Biotech's (SZSE:301393) Strong Earnings

Additional Considerations Required While Assessing Suzhou Highfine Biotech's (SZSE:301393) Strong Earnings

在评估苏州海鑫生物(SZSE:301393)强劲收益时需要考虑其他因素
Simply Wall St ·  2024/11/06 01:55

Investors were disappointed with Suzhou Highfine Biotech Co., Ltd.'s (SZSE:301393) earnings, despite the strong profit numbers. We think that the market might be paying attention to some underlying factors that they find to be concerning.

投资者对苏州中芯生物科技股份有限公司(SZSE:301393)的收益感到失望,尽管利润数字强劲。我们认为市场可能正在关注一些他们认为令人担忧的潜在因素。

big
SZSE:301393 Earnings and Revenue History November 6th 2024
SZSE:301393 历史数据收益和营业收入 2024年11月6日

The Impact Of Unusual Items On Profit

除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。

For anyone who wants to understand Suzhou Highfine Biotech's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥8.8m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. If Suzhou Highfine Biotech doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

对于任何想了解苏州中芯生物科技利润超越法定数字的人来说,重要的是要注意,在过去十二个月中,法定利润从880万元的飞凡项目中获得。我们不能否认,更高的利润通常让我们感到乐观,但我们更希望利润能够持续。当我们对成千上万家上市公司的数字进行分析时,我们发现,一年中来自飞凡项目的增长通常不会在下一年重复。这并不奇怪,鉴于其名称。如果苏州中芯生物科技看不到该贡献再现,那么其他条件相等,我们预期其今年的利润将下降。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Suzhou Highfine Biotech.

注意:我们始终建议投资者检查资产负债表的实力。点击这里查看我们对苏州中芯生物科技的资产负债表分析。

Our Take On Suzhou Highfine Biotech's Profit Performance

我们对苏州中芯生物科技的利润表现看法

We'd posit that Suzhou Highfine Biotech's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Suzhou Highfine Biotech's statutory profits are better than its underlying earnings power. Sadly, its EPS was down over the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Suzhou Highfine Biotech's balance sheet by clicking here.

我们认为苏州海芬生物技术的法定收入并不完全反映其持续生产力,因为涉及了一个较大的飞凡项目。因此,我们认为苏州海芬生物技术的法定利润可能优于其潜在盈利能力。遗憾的是,过去十二个月其每股收益下降。本文的目标是评估我们能否依靠法定收入来体现公司的潜力,但还有更多因素需要考虑。投资者除了考虑收入外,还要考虑公司资产负债表的实力。我们进行了一些分析,您可以点击这里查看我们对苏州海芬生物技术资产负债表的看法。

Today we've zoomed in on a single data point to better understand the nature of Suzhou Highfine Biotech's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

今天,我们聚焦于一个数据点,以更好地了解苏州海芬生物技术利润的性质。但如果您能集中注意力于细节,就总有更多发现。例如,许多人认为高净资产回报是有利的商业经济指标,而另一些人喜欢“跟随资金”并寻找内部人员正在购买的股票。因此,您可能希望查看这些拥有高净资产回报的公司的免费收集,或者这些拥有高内部所有权股票的列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发